[Progress in hepatitis C treatment]

Med Clin (Barc). 2013 Nov 16;141(10):447-52. doi: 10.1016/j.medcli.2013.01.041. Epub 2013 Apr 17.
[Article in Spanish]

Abstract

Recent approval of new protease inhibitors (boceprevir and telaprevir) for the treatment of chronic hepatitis C, genotype 1, has meant a significant increase in the sustained viral response both in naive and previously treated patients. However, such efficacy increase has been accompanied by an increase in adverse events, sometimes serious, and new practical issues including different approaches to stop treatment and drug interactions that recommend a close follow-up of patients. The efficacy and safety of triple therapy in special populations such as cirrhotic and transplanted patients is less known and has some particulars, meaning that its administration requires an exhaustive monitoring.

Keywords: Boceprevir; Hepatitis C; Inhibidores de la proteasa; Interferón pegilado; Pegylated interferon; Protease inhibitors; Ribavirina; Ribavirine; Telaprevir.

Publication types

  • Review

MeSH terms

  • Anemia / chemically induced
  • Antiviral Agents / adverse effects
  • Antiviral Agents / therapeutic use*
  • Clinical Trials, Phase III as Topic
  • Drug Eruptions / etiology
  • Drug Therapy, Combination
  • Hepatitis C, Chronic / blood
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / virology
  • Humans
  • Interferon-alpha / therapeutic use
  • Liver Cirrhosis / etiology
  • Liver Transplantation
  • Multicenter Studies as Topic
  • Oligopeptides / adverse effects
  • Oligopeptides / therapeutic use*
  • Polyethylene Glycols / administration & dosage
  • Proline / adverse effects
  • Proline / analogs & derivatives*
  • Proline / therapeutic use
  • Protease Inhibitors / adverse effects
  • Protease Inhibitors / therapeutic use*
  • Pruritus / chemically induced
  • RNA, Viral / blood
  • Randomized Controlled Trials as Topic
  • Recurrence
  • Ribavirin / therapeutic use
  • Treatment Outcome
  • Viral Load
  • Viremia / drug therapy

Substances

  • Antiviral Agents
  • Interferon-alpha
  • Oligopeptides
  • Protease Inhibitors
  • RNA, Viral
  • Polyethylene Glycols
  • Ribavirin
  • telaprevir
  • N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
  • Proline